Premium
Development of medical termination of pregnancy: a review
Author(s) -
Ho PC
Publication year - 2017
Publication title -
bjog: an international journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.157
H-Index - 164
eISSN - 1471-0528
pISSN - 1470-0328
DOI - 10.1111/1471-0528.14905
Subject(s) - mifepristone , misoprostol , medicine , prostaglandin analogue , pregnancy , regimen , gestation , medical abortion , early pregnancy factor , obstetrics , gynecology , abortion , prostaglandin , genetics , biology
The synthesis of mifepristone, an antiprogestin blocking the action of progesterone at the receptor level, started a new era of medical termination of pregnancy ( MTOP ). The initial results of MTOP with mifepristone alone were disappointing; however, mifepristone can sensitise the myometrium to the action of prostaglandins. Clinical trials have shown that the sequential administration of mifepristone followed 1–2 days later by a prostaglandin analogue is a safe, effective, and acceptable method for MTOP . This article will review the events and challenges leading to the development of the current evidence‐based and yet off‐label regimen for first‐trimester MTOP . Tweetable abstract This article reviews the events and challenges in the development of medical termination of pregnancy.